Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability-Reference-Cited by-同舟云学术

Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability

Published:2008-04-12 Issue:12 Volume:57 Page:1879-1890
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Schmidt Michael M.,Thurber Greg M.,Wittrup K. Dane

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s00262-008-0518-1.pdf

Reference40 articles.

1. Ackerman M, Chalouni C, Raman V, Schmidt M, Ritter G, Mellman I, Wittrup KD (2008) A33 antigen displays persistent surface expression. Cancer Immunol Immunother (in press)

2. Adams GP et al (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61:4750–4755

3. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23:1147–1157

4. Austin CD et al (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268–5282

5. Baxter LT, Jain RK (1991) Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 41:5–23

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity;Nature Immunology;2024-08-07

2. Transport cocktails for cancer therapeutics;Physical Review Research;2024-08-05

3. Increased imaging ligand hydrophilicity and improved pharmacokinetic properties provides enhanced in vivo targeting of fibroblast activation protein;npj Imaging;2024-08-02

4. Effectors of the Future: Universal Chimeric Antigen Receptor;Transfusion Medicine and Hemotherapy;2024-07-15

5. CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells;Current Cancer Drug Targets;2024-07